Regentis Biomaterials Ltd. (RGNT)
NASDAQ: RGNT · Real-Time Price · USD
7.49
-0.01 (-0.13%)
At close: Dec 5, 2025, 4:00 PM EST
7.30
-0.19 (-2.54%)
After-hours: Dec 5, 2025, 8:00 PM EST
Company Description
Regentis Biomaterials is a regenerative medicine company dedicated to developing innovative tissue repair solutions that seek to restore the health and enhance the quality of life of patients.
Our current efforts are focused on orthopedic treatments using our Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue.
Our lead product candidate is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.
GelrinC was approved as a device, with a Conformité Européene, or CE, mark in Europe in 2017. We plan to identify strategic partners in Europe to bring our product to market.
Regentis Biomaterials Ltd.
| Country | Israel |
| Founded | 2004 |
| IPO Date | Dec 4, 2025 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Dr. Eli Hazum |
Contact Details
Address: 60 Medinat Hayehudim Herzliya, 4676652 Israel | |
| Phone | +972 (9) 960-1917 |
| Website | regentis.co.il |
Stock Details
| Ticker Symbol | RGNT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $8.00 |
| CIK Code | 0001912966 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ehud Geller | Director, Chairman |
| Mr. Jeff Dykan | Director |
| Mr. Keith Valentine | Director(1) |
| Dr. Eli Hazum | Chief Executive Officer |
| Mr. Arie Gordashnikov | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 5, 2025 | 6-K | Report of foreign issuer |
| Dec 4, 2025 | 424B3 | Prospectus |
| Dec 3, 2025 | CERT | Certification by an exchange approving securities for listing |
| Oct 24, 2025 | FWP | Free Writing Prospectus |
| Oct 24, 2025 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Oct 6, 2025 | FWP | Free Writing Prospectus |
| Sep 30, 2025 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Sep 9, 2025 | 8-A12B | Registration of securities |
| Sep 9, 2025 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Jul 7, 2025 | FWP | Free Writing Prospectus |